Clinical Trial Update: HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients [Phase 3]

View source ↗

Summary

The HOPE-B Phase 3 trial of AMT-061 (fidanacogene elaparvovec) for Hemophilia B has completed, with results posted in October 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• AMT-061 (fidanacogene elaparvovec)

Snippet

Sponsor: CSL Behring | Conditions: Hemophilia B | Phase 3 | Status: COMPLETED | Results posted: 2022-10-10